Nicotinic agonists, antagonists, and modulators from natural sources

Cellular and Molecular Neurobiology

Volumn 25, Issue 3-4, 2005, Pages 513-552

  Daly, John W ^a,b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anatoxin; Cocaine; Cytisine; Dihydro beta erythroidine; Epibatidine; Epiquinamide; Galanthamine; Histrionicotoxin; Ibogaine; Methyllycaconitine; Muscarine; Nicotine; Noncompetitive antagonists; Tubocurarine

Indexed keywords

2 (3 PYRIDINYL)QUINUCLIDINE; 2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 (6 CHLORO 3 PYRIDAZINYL) 3,8 DIAZABICYCLO[3.2.1]OCTANE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; A 79814; A 84543; A 85865; ANABASINE; ANATOXIN; CMI 934; COCAINE; CODEINE; COTININE; CYTISINE; DECAHYDROQUINOLINE DERIVATIVE; EPIBATIDINE; EPIQUINAMIDE; ERYTHRINA ALKALOID; FERRUGININE; GALANTAMINE; HISTRIONICOTOXIN; IBOGAINE; IVERMECTIN; LOBELINE; METHYLCACONITINE; MUSCARINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NATURAL PRODUCT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NNC 90 0270; PYRROLIZIDINE DERIVATIVE; SPARTEINE; SPIRO COMPOUND; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SSR 591813; STRYCHNINE; TUBOCURARINE CHLORIDE; UB 165; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE;

ADDICTION; ALLOSTERISM; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANXIETY DISORDER; ARTHROPOD; ATTENTION DEFICIT DISORDER; AUTISM; BINDING COMPETITION; CLINICAL TRIAL; CORAL; DEPRESSION; DRUG ACTIVITY; DRUG DESIGN; DRUG ISOLATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENANTIOSELECTIVITY; EPILEPSY; ERYTHRINA; FROG; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPERTENSION; HYPOTHERMIA; IC 50; MOLLUSC; NEUROMODULATION; NONHUMAN; OOCYTE; PARKINSONISM; PLANT; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; RESPIRATORY FAILURE; REVIEW; SCHIZOPHRENIA; SEIZURE; SMOKING CESSATION; SNAIL; SNAKE; STROKE; ULCERATIVE COLITIS; VOMITING; XENOPUS;

ANIMALS; HUMANS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PLANTS; TOXINS, BIOLOGICAL; VENOMS;

STRYCHNOS TOXIFERA;

EID: 23944472732     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-005-3968-4     Document Type: Review

References (240)

1. 3H]- Methylcarbamylcholine, a new radioligand for studying brain nicotinic receptors. Biochem. Pharmacol. 35:4199-4202.
2. Abood, L. G., Salles, K. S., and Maiti, K. (1988). Structure-activity studies of carbamate and other esters: Agonists and antagonists to nicotine. Pharmacol. Biochem. Behav. 30:403-408.
3. Abreo, M. A., Lin, N.-H., Garvey, D. S., Gunn, D. E., Hettinger, A.-M., Wasicak, J. T., Pavlik, P. A., Martin, Y. C., Donnelly-Roberts, D. L., Anderson, D. J., Sullivan, J. P., Williams, M., Arneric, S. P., and Holladay, M. W. (1996). Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:817-825.
4. Aiyar, V. N., Beim, M. H., Hanna, T., Jacyno, J., Roth, S. H., and Wilkens, J. L. (1979). The principal toxin of Delphinium brownii, and its mode of action. Experientia 35:1367-1368.
5. Albuquerque, E. X., Barnard, E. A., Chiu, T. M., Lapa, A. J., Dolly, J. O., Jansson, S.-E., Daly, J. W., and Witkop, B. (1973). Acetylcholine receptor and ion conductance modulator sites at the murine neuromuscular junction: Evidence from specific toxin reactions. Proc. Natl. Acad. Sci. USA 70:949-953.
6. Albuquerque, E. X., Tsai, M.-C., Aronstam, R. S., Witkop, B., Eldefrawi, A. T., and Eldefrawi, M. E. (1980). Phencyclidine interactions with the ion channel of the acetylcholine receptor and electrogenic membrane. Proc. Natl. Acad. Sci. USA 77:1224-1228.
7. 3H] methylcarbamylcholine in rat brain. Eur. J. Pharmacol. 253:261-267.
8. 3H] ABT-418: A novel cholinergic channel ligand. J. Pharmacol. Exp. Ther. 273:1434-1441.
9. Archer, S., Lands, A. M., and Lewis, T. R. (1962). Isomeric 1-acetoxytropine methiodides. J. Med. Pharm. Chem. 5:423-430.
10. Arias, H. R. (1998). Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Biochim. Biophys. Acta 1376:173-220.
11. Aronstam, R. S., Daly, J. W., Spande, T. F., Narayanan, T. K., and Albuquerque, E. X. (1986). Interaction of gephyrotoxin and indolizidine alkaloids with the nicotinic acetylcholine receptor-ion channel complex of Torpedo electroplax. Neurochem. Res. 11, 8:1227-1240.
12. Aronstam, R. S., Edwards, M. W., Daly, J. W., and Albuquerque, E. X. (1988). Interactions of piperidine derivatives with the nicotinic cholinergic receptor complex from Torpedo electric organ. Neurochem. Res. 13:171-176.
13. 3H]perhydrohistrionicotoxin binding to Torpedo ocellata electroplax by effectors of the acetylcholine receptor. J. Biol. Chem. 256:2843-2850.
14. 3H]phencyclidine to the nicotinic receptor-ion channel complex of Torpedo electroplax. Inhibition by histrionicotoxins and derivatives. Biochem. Pharmacol. 34:3037-3047.
15. Avalos, M., Parker, M. J., Maddox, F. N., Carroll, F. I., and Luetje, C. W. (2002). Effects of pyridine ring substitutions on affinity, efficacy, and subtype selectivity of neuronal nicotinic receptor agonist epibatidine. J. Pharmacol. Exp. Ther. 302:1246-1252.
16. Avenoza, A., Busto, J. H., Cativiela, C., Dordal, A., Frigola, J., and Peregrina, J. M. (2002). Synthesis, activity and theoretical study of ABT-418 analogues. Tetrahedron 58:4505-4511.
17. Ayers, J. T., Dwoskin, L. P., Deaciuc, A. G., Grinevich, V. P., Zhu, J., and Crooks, P. A. (2002). bis-Azaaromatic quaternary ammonium analogues: Ligands for α4β2* and α7* subtypes of neuronal nicotinic receptors. Bioorg. Med. Chem. Lett. 12:3067-3071.
18. Badio, B., and Daly, J. W. (1994). Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:563-569.
19. Badio, B., Garraffo, H. M., Padgett, W. L., Greig, N. H., and Daly, J. W. (1997a). Pseudophrynaminol: A potent noncompetitive blocker of nicotinic receptor-channels. Biochem. Pharmacol. 53:671-676.
20. Badio, B., Garraffo, H. M., Plummer, C. V., Padgett, W. L., and Daly, J. W. (1997b). Synthesis and nicotinic activity of epiboxidine: An isoxazole analogue of epibatidine. Eur. J. Pharmacol. 321:189-194.
21. Badio, B., Garraffo, H. M., Spande, T. F., and Daly, J. W. (1994). Epibatidine: Discovery and definition as a potent analgesic and nicotinic agonist. Med. Chem. Res. 4:440-448.
22. Badio, B., Shi, D., Garraffo, H. M., and Daly, J. W. (1995). Antinociceptive effects of the alkaloid epibatidine: Further studies on involvement of nicotinic receptors. Drug Dev. Res. 36:46-59.
23. Badio, B., Padgett, W. L., and Daly, J. W. (1997c). Ibogaine: A potent noncompetitive blocker of ganglionic/neuronal nicotinic receptors. Mol. Pharmacol. 51:1-5.
24. Badio, B., Shi, D., Shin, Y., Hutchinson, K. D., Padgett, W. L., and Daly, J. W. (1996). Spiropyrrohzidines: A new class of blockers of nicotinic receptors. Biochem. Pharmacol. 52:933-939.
25. Balestra, B., Vailati, S., Moretti, M., Hanke, W., Clementi, F., and Gotti, C. (2000). Chick optic lobe contains a developmentally regulated α2α5β2 nicotinic receptor subtype. Mol. Pharmacol. 58:300-311.
26. Balboni, G., Marastoni, M., Merighi, S., Borea, P. A., and Tomatis, R. (2000). Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors. Eur. J. Med. Chem. 35:979-988.
27. 4 subtypes. Mol. Pharmacol. 59:1410-1417.
28. Barlocco, D., Cignarella, G., Tondi, D., Vianello, P., Villa, S., Bartolini, A., Ghelardini, C., Galeotti, N., Anderson, D. J., Kuntzweiler, T. A., Colombo, D., and Toma, L. (1998). Mono- and disubstituted-3,8- diazabicyclo[3.2.1]octane derivatives as analgesics structurally related to epibatidine: Synthesis, activity, and modeling. J. Med. Chem. 41:674-681.
29. Battersby, A. R., and Hodson, H. F. (1968). Alkaloids of calabash curare and Strychnos species. In Manske, R. H. F. (ed.), The Alkaloids, Chemistry and Physiology, Vol. 11, Academic Press, New York, pp. 189-204.
30. Beach, J. W., Damaj, M. I., Jonnala, R. R., Terry, A. V., Jr., and Buccafusco, J. J. (1998). Synthesis and in vivo and in vitro evaluation of isoarecolone and derivatives. Med. Chem. Res. 8:510-522.
31. Bencherif, M., Eisenhour, C. M., Prince, R. J., Lippiello, P. M., and Lukas, R. J. (1995). The "calcium antagonist" TMB-8 [3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester] is a potent, non-competitive functional antagonist at diverse nicotinic acetylcholine receptor subtypes. J. Pharmacol. Exp. Ther. 275:1418-1426.
32. Bencherif, M., Lovette, M. E., Fowler, K. W., Arrington, S., Reeves, L., Caldwell, W. S., and Lippiello, P. M. (1996). RJR-2403: A nicotinic agonist with CNS selectivity I. In vitro characterization. J. Pharmacol. Exp. Ther. 279:1413-1421.
33. Bencherif, M., Schmitt, J. D., Bhatti, B. S., Crooks, P., Caldwell, W. S., Lovette, M. E., Fowler, K., Reeves, L., and Lippiello, P. M. (1998). The heterocyclic substituted pyridine derivative (±)-2-(-3-pyridinyl)-1- azabicyclo[2.2.2]octane (RJR-2429).: A selective ligand at nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 284:886-894.
34. Bertrand, S., Patt, J. T., Spang, J. E., Westera, G., Schubigcor, P. A., and Bertrand, D. (1999). Neuronal nAChR stereoselectivity to non-natural epibatidine derivatives. FEBS Lett. 450:273-279.
35. Bick, R. C., Gillard, J. W., and Leow, H. M. (1979a). Alkaloids of Darlingia darlingiana. Aust. J. Chem. 32:2523-2536.
36. Bick, R. C., Gillard, J. W., and Leow, H.-M. (1979b). Alkaloids of Darlingia ferruginea. Australian J. Chem. 32:2537-2543.
37. Bikádi, Z., and Simonyi, M. (2003). Muscarinic and nicotinic cholinergic agonists: Structural analogies and discrepancies. Curr. Med. Chem. 10:2611-2620.
38. Brier, T. J., Mellor, I. R., Tikhonov, D. B., Neagoe, I., Shao, Z., Brierley, M. J., Stromgaard, K., Jaroszewski, J. W., Krogsgaard-Larsen, P., and Usherwood, P. N. R. (2003). Contrasting actions of philantho toxin - 343 and philanthotoxin-(12) on human muscle nicotinic acetylcholine receptors. Mol. Pharmacol. 64:954-964.
39. Briggs, C. A., Anderson, D. J., Brioni, J. D., Buccafusco, J. J., Buckley, M. J., Campbell, J. E., Decker, M. W., Donnelly-Roberts, D., Elliott, R. L., Gopalakrishnan, M., Holladay, M. W., Hui, Y.-H., Jackson, W. J., Kim, D. J. B., Marsh, K. C., O'Neill, A., Prendergast, M. A., Ryther, K. B., Sullivan, J. P., and Arneric, S. P. (1997). Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57:231-241.
40. 3 receptor. Eur. J. Pharmacol. 452:137-144.
41. Brown, L. L., Kulkarni, S., Pavlova, O. A., Koren, A. O., Mukhin, A. G., Newman, A. H., and Horti, A. G. (2002). Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl) vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J. Med. Chem. 45:2841-2849.
42. 4 nicotinic receptors. Neurosci. Res. 42:57-63.
43. Bunnelle, W. H., Dart, M. J., and Schrimpf, M. R. (2004). Design of ligands for the nicotinic acetylcholine receptor: The quest for selectivity. Curr. Topics Med. Chem. 4:299-334.
44. Bunnelle, W. H., and Decker, M. W. (2003). Neuronal nicotinic acetylcholine receptor ligands as potential analgesics. Exp. Opin. Ther. Patents 13:1003-1021.
45. Cachelin, A. B., and Rust, G. (1995). β-Subunits co-determine the sensitivity of rat neuronal nicotinic receptors to antagonists. Pflügers Arch-Eur. J. Physiol. 429:449-451.
46. Carbonnelle, E., Sparatore, F., Canu-Boido, C., Salvagno, C., Baldani-Guerra, B., Terstappen, G., Zwart, R., Vijverberg, H., Clementi, F., and Gotti, C. (2003). Nitrogen substitution modifies the activity of cystisine on neuronal nicotinic receptor subtypes. Eur. J. Pharmacol. 471:85-96.
47. Carroll, F. I., Lee, J. R., Navarro, H. A., Brieaddy, L. E., Abraham, P., Damaj, M. I., and Martin, B. R. (2001a). Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′- substituted-3′-phenyl-5′-pyridinyl)-7-azabicyclo[2.2.1]-heptanes. Novel nicotinic antagonist. J. Med. Chem. 44:4039-4041.
48. Carroll, F. I., Lee, J. R., Navarro, H. A., Ma, W., Brieaddy, L. E., Abraham, P., Damaj, M. I., and Martin, B. R. (2002). Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′,3′-disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1] heptanes: Epibatidine analogues. J. Med. Chem. 45:4755-4761.
49. Carroll, F. I., Liang, F., Navarro, H. A., Brieaddy, L. E., Abraham, P., Damaj, M. I., and Martin, B. R. (2001b). Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′- substituted-5′-pyridinyl)-7-azabicyclo[2.2.1]-heptanes. Epibatidine analogues. J. Med. Chem. 44:2229-2237.
50. Caulfield, M. P., and Birdsall, N. J. M. (1998). International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptor. Pharmacol. Rev. 50:279-290.
51. Cheng, Y.-X., Dukat, M., Dowd, M., Fiedler, W., Martin, B., Damaj, M. I., and Glennon, R. A. (1999). Synthesis and binding of 6,7,8,9-tetrahydro-5H- pyrido[3,4-d]azepine and related ring-opened analogs at central nicotinic receptors. Eur. J. Med. Chem. 34:177-190.
52. Cheng, J., Zhang, C., Stevens, E. D., Izenwasser, S., Wade, D., Chen, S., Paul, D., and Trudell, M. L. (2002). Synthesis and biological evaluation at nicotinic acetylcholine receptors of N-arylalkyl- and N-aryl-7-azabicyclo[2.2.1] heptanes. J. Med. Chem. 45:3041-3047.
53. Choi, K. J., Cha, J. H., Cho, Y. S., Pae, A. N., Jin, C., Yook, J., Cheon, H. G., Jeong, D., Kong, J. Y., and Koh, H. Y. (1999). Binding affinities of 3-(3-phenylisoxazol-5-yl)methylidene 1-azabicycles to acetylcholine receptors. Bioorg. Med. Chem. Lett. 9:2795-2800.
54. Clarke, P. B. S., and El-Bizri, H. (1994). Blockade of nicotinic receptor-mediated release of dopamine from striatal synaptosomes by chlorisondamine and other nicotinic antagonists administered in vitro. Br. J. Pharmacol. 111:406-413.
55. Clarke, P. B. S. (1992). The fall and rise of neuronal α-bungarotoxin binding proteins. Trends Pharmacol. Sci. 13:407-413.
56. 2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. 306:407-420.
57. Cosford, N. D. P., Bleicher, L., Herbaut, A., McCallum, J. S., Vernier, J.-M., Dawson, H., Whitten, J. P., Adams, P., Chavez-Noriega, L., Correa, L. D., Crona, J. H., Mahaffy, L. S., Menzaghi, F., Rao, T. S., Reid, R., Sacaan, A. I., Santori, E., Stauderman, K. A., Whelan, K., Lloyd, G. K., and McDonald, I. A. (1996). (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrohdinyl)pyridine maleate (SIB-1508Y): A novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 39:3235-3237.
58. Cox, C. D., Malpass, J. R., Gordon, J., and Rosen, A. (2001). Synthesis of epibatidine isomers: Endo-5-and 6-(6′-chloro-3′-pyridyl-2- azabicyclo[2.2.1]heptanes. J. Chem. Soc., Perkin Trans. 1 2372-2379.
59. Culver, P., Burch, M., Potenza, C., Wasserman, L., Fenical, W., and Taylor, P. (1985). Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones. Mol. Pharmacol. 28:436-444.
60. Dale, H. H. (1914). The action of certain esters and ethers of choline, and their relation to muscarine. J. Pharmacol. Exp. Ther. 6:147-190.
61. Dale, H. H. (1954). The beginnings and the prospects of neurohumoral transmission. Pharmacol. Rev. 6:7-13.
62. 2 neuronal nicotinic acetylcholine receptor. Pesticide Biochem. Physiol. 64:55-61.
63. Daly, J. W. (2003). Ernest Guenther award in chemistry of natural products. Amphibian skin: A remarkable source of biologically active arthropod alkaloids. J. Med. Chem. 46:445-452.
64. Daly, J. W., Gupta, T. H., Padgett, W. L., and Pei, X.-F. (2000). 6β-Acyloxy(nor)tropanes: Affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J. Med. Chem. 43:2514-2522.
65. Daly, J. W., Nishizawa, Y., Edwards, M. W., Waters, J. A., and Aronstam, R. S. (1991a). Nicotinic receptor-elicited sodium flux in rat pheochromocytoma PC12 cells: Effects of agonists, antagonists, and non-competitive blockers. Neurochem. Res. 16:489-500.
66. Daly, J. W., Nishizawa, Y., Padgett, W. L., Tokuyama, T., McCloskey, P. J., Waykole, L., Schultz, A. G., and Aronstam, R. S. (1991b). Decahydroquinoline alkaloids: Noncompetitive blockers for nicotinic acetylcholine receptor-channels in pheochromocytoma cells and Torpedo electroplax. Neurochem. Res. 16:1207-1212.
67. Daly, J. W., Nishizawa, Y., Padgett, W. L., Tokuyama, T., Smith, A. L., Holmes, A. B., Kibayashi, C., and Aronstam, R. S. (1991c). 5,8-Disubstituted indolizidines: A new class of noncompetitive blockers for nicotinic receptor-channels. Neurochem. Res. 16:1213-1218.
68. Damaj, M. I., Glassco, W., Aceto, M. D., and Martin, B. R. (1999). Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J. Pharmacol. Exp. Ther. 291:390-398.
69. Damaj, M. I., Glassco, W., Dukat, M., May, E. L., Glennon, R. A., and Martin, B. R. (1996). Pharmacology of novel nicotinic analogs. Drug Dev. Res. 38:177-187.
70. 3H]methyllycaconitine: A new radioligand for labeling α7-type neuronal nicotinic acetylcholine receptors. Neuropharmacology 38:679-690.
71. 125I]IPH, an epibatidine analog, binds with high affinity to neuronal nicotinic cholinergic receptors. J. Pharmacol. Exp. Ther. 282:445-451.
72. Decker, M. W., Anderson, D. J., Brioni, J. D., Donnelly-Roberts, D. L., Diana, L., Kang, C. H., O'Neill, A. B., Piattoni-Kaplan, M., Swanson, S., and Sullivan, J. P. (1995a). Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors. Eur. J. Pharmacol. 280:79-89.
73. Decker, M. W., Brioni, J. D., Bannon, A. W., and Arneric, S. P. (1995b). Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS Thereutics. Life Sci. 56:545-570.
74. 125I-α- bungarotoxin receptor subtypes. Mol. Pharmacol. 47:164-171.
75. Devlin, J. P., Edwards, O. E., Gorham, P. R., Hunter, H. R., Pike, R. K., and Stavric, B. (1977). Anatoxin-a, a toxic alkaloid from Anabaena flos-aquae NRC-44h. Can. J. Chem. 55:1367-1371.
76. Dukat, M., Damaj, I. M., Young, R., Vann, R., Collins, A. C., Marks, M. J., Martin, B. R., and Glennon, R. A. (2002a). Functional diversity among 5-substituted nicotine analogs; in vitro and in vivo investigations. Eur. J. Pharmacol. 435:171-180.
77. Dukat, M., Dowd, M., Damaj, M. I., Martin, B., El-Zahabi, M. A., and Glennon, R. A. (1999). Synthesis, receptor binding and QSAR studies on 6-substituted nicotine derivatives as cholinergic ligands. Eur. J. Med. Chem. 34:31-40.
78. Dukat, M., El-Zahabi, M., Ferretti, G., Damaj, M. I., Martin, B. R., Young, R., and Glennon, R. A. (2002b). (-)-6-n-Propylnicotine antagonizes the antinociceptive effects of (-)-nicotine. Bioorg. Med. Chem. Lett. 12:3005-3007.
79. Dukat, M., Fredler, W., Dumas, D., Damaj, I., Martin, B. R., Rosecrans, J. A., James, J. R., and Glennon, R. A. (1996). Pyrrolidine-modified and 6-substituted analogs of nicotine: A structure-affinity investigation. Eur. J. Med. Chem. 31:875-888.
80. 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol. Pharmacol. 64:1283-1294.
81. Efange, S. M. N., Tu, Z., von Hohenberg, K., Francesconi, L., Howell, R. C., Rampersad, M. V., Todaro, L. J., Papke, R. L., and Kung, M.-P. (2001). 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: Synthesis and preliminary pharmacological characterization. J. Med. Chem. 44:4704-4715.
82. Eldefrawi, A. T., Eldefrawi, M. E., Albuquerque, E. X. Oliveira, A. C., Mansour, N., Adler, M., Daly, J. W., Brown, G. B., Burgermeister, W., and Witkop, B. (1977). Perhydrohistrionicotoxin: A potential ligand for the ion conductance modulator of the acetylcholine receptor. Proc. Natl. Acad. Sci. U.S.A 74:2172-2176.
83. Elliott, R. L., Kopecka, H., Gunn, D. E., Lin, N.-H., Garvey, D. S., Ryther, K. B., Holladay, M. W., Anderson, D. J., Campbell, J. E., Sullivan, J. P., Buckley, M. J., Gunther, K. L., O'Neill, A. B., Decker, M. W., and Arneric, S. P. (1996). 2-(Aryloxymethyl)azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands. Bioorg. Med. Chem. Lett. 6:2283-2288.
84. Elliott, R. L., Ryther, K. B., Anderson, D. J., Piattoni-Kaplan, M., Kuntzweiler, T. A., Donnelly-Roberts, D., Arneric, S. P., and Holladay, M. W. (1997). Novel 2-(2′-furo[3,2-b]pyridinyl)pyrrolidines: Potent neuronal nicotinic acetylcholine receptor ligands. Bioorg. Med. Chem. Lett. 7:2703-2708.
85. Elliott, R. L., Ryther, K. B., Anderson, D. J., Raszkiewicz, J. L., Campbell, J. E., Sullivan, J. P., and Garvey, D. S. (1995). Phenyl pyrrolidine analogues as potent nicotinic acetylcholine receptor (nAChR) ligands. Bioorg. Med. Chem. Lett. 5:991-996.
86. 4 receptor subtype. J. Pharmacol. Exp. Ther. 288:1143-1150.
87. Erspamer, V., and Benati, O. (1953). Identification of murexine as β-[imidazolyl-(4)]-acryl-choline. Experientia 117:161-162.
88. 4 properties. Eur. J. Pharmacol. 466:31-39.
89. 125/123I]5-Iodo-3-pyridyl ethers: Syntheses and binding to neuronal nicotinic acetylcholine receptors. Nucl. Med. Biol. 28:911-921.
90. Felder, C. C., Bymaster, F. P., Ward, J., and DeLapp, N. (2000). Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43:4333-4353.
91. Fenical, W., Okuda, R. K., Bandurraga, M. M., Culver, P., and Jacobs, R. S. (1981). Lophotoxin: A novel neuromuscular toxin from pacific sea whips of the genus Lophogorgia. Science 212:1512-1514.
92. Ferretti, G., Dukat, M., Giannella, M., Piergentili, A., Pigini, M., Quaglia, W., Damaj, M. I., Martin, B. R., and Glennon, R. A. (2003). Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors. Bioorg. Med. Chem. Lett. 13:733-735.
93. Fitch, R. W., Garraffo, H. M., Spande, T. F., Yeh, H. J. C., and Daly, J. W. (2003a). Bioassay-guided isolation of epiquinamide, a novel quinolizidine alkaloid and nicotinic agonist from an Ecuadoran poison frog, Epipedobates tricolor. J. Nat. Prod. 66:1345-1350.
94. Fitch, R. W., Pei, X.-F., Kaneko, Y., Gupta, T., Shi, D., Federova, I., and Daly, J. W. (2004). Homoepiboxidines: Further potent agonists for nicotinic receptors. Bioorg. Med. Chem. 12:179-190.
95. Fitch, R. W., Xiao, Y., Kellar, K. J., and Daly, J. W. (2003b). Membrane potential fluorescence: A rapid and highly sensitive assay for nicotinic receptor channel function. Proc. Natl. Acad. Sci. U.S.A. 100:4909-4914.
96. Flammia, D., Dukat, M., Damaj, M. I., Martin, B., and Glennon, R. A. (1999). Lobeline: Structure-affinity investigation of nicotinic acetylcholinergic receptor binding. J. Med. Chem. 42:3726-3731.
97. Folkers, K., and Major, R. T. (1937). Isolation of erythroidine, an alkaloid of curare action, from Erythrina americana Mill. J. Am. Chem. Soc. 59:1850-1851.
98. 7 nicotinic acetylcholine receptor by a quaternary analog of cocaine. Mol. Pharmacol. 60:71-79.
99. 4 subunits. Mol. Pharmacol. 58:109-119.
100. Fryer, J. D., and Lukas, R. J. (1999). Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine. J. Pharmacol. Exp. Ther. 288:88-92.
101. Garvey, D. S., Wasicak, J. T., Decker, M. W., Brioni, J. D., Buckley, M. J., Sullivan, J. P., Carrera, G. M., Holladay, M. W., Arneric, S. P., and Williams, M. (1994). Novel isoxazoles with interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities. J. Med. Chem. 37:1055-1059.
102. Gentry, C. L., and Lukas, R. J. (2001). Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes. J. Pharmacol. Exp. Ther. 299:1038-1048.
103. Ghelardini, C., Galeotti, N., Barlocco, D., and Bartolini, A. (1997). Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Dev. Res. 40:251-258.
104. Ghelardini, C., Galeotti, N., Gualtieri, F., Bellucci, C., Manetti, D., Borea, P. A., and Bartolini, A. (1997). Antinociceptive property of the nicotinic agonist AG-4 in rodents. Drug Dev. Res. 41:1-9.
105. Glennon, R. A., and Dukat, M. (2000). Central nicotinic receptor ligands and pharmacophores. Pharm. Acta Helv. 74:103-114.
106. 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur. J. Pharmacol. 438:99-105.
107. 3H]epibatidine to rat brain membranes. NeuroReport 10:1631-1636.
108. Gohlke, H., Gündisch, D., Schwartz, S., Seitz, G., Tilotta, M. C., and Wegge, T. (2002). Synthesis and nicotinic binding studies on enantiopure diazine analogues of the novel (2-chloro-5-pyridyl)-9-azabicyclo[4.2.1]non-2-ene UB-165. J. Med. Chem. 45:1064-1072.
109. 3 nicotinic acetylcholine receptor. J. Med. Chem. 46:2031-2048.
110. Gopalakrishnan, M., Buisson, B., Touma, E., Giordano, T., Campbell, J. E., Hu, I. C., Donnelly-Roberts, D., Arneric, S. P., Bertrand, D., and Sullivan, J. P. (1995). Stable expression and pharmacological properties of the human α1 nicotinic acetylcholine receptor. Eur. J. Pharmacol. 290:237-246.
111. 2 receptor. J. Pharmacol. Exp. Ther. 276:289-297.
112. Grady, S. R., Meinerz, N. M., Cao, J., Reynolds, A. M., Picciotto, M. R., Bhangeux, J.-P., McIntosh, J. M., Marks, M. J., and Collins, A. C. (2001). Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: A function mediated by a different nAChR than dopamine release from striatum. J. Neurochem. 76:258-268.
113. Guandalini, L., Dei, S., Gualtieri, F., Romanelli, M. N., Scapecchi, S., Teodori, E., and Varani, K. (2002). Synthesis of hexahydro-2-pyrindine (= hexahydrocyclo-penta[c]pyridine) derivatives as conformationally restricted analogs of the nicotinic ligands arecolone and isoarecolone. Hev. Chim. Acta 85:96-107.
114. Gündisch, D., Kämpchen, T., Schwarz, S., Seitz, G., Siegl, J., and Wegge, T. (2002). Syntheses and evaluation of pyridazine and pyrimidine containing bioisoteres of (±)-pyrido[3.4-b]homotropane and pyrido-[3.4-b]tropane as novel nAChR ligands. Bioorg. Med. Chem. 10:1-9.
115. Haefely, W. (1974). Effects of various nicotine-like agents in the cat superior cervical ganglion in situ. Naunyn-Schmiedeberg's Arch. Pharmacol. 281:93-117.
116. Hardick, D. J., Blagbrough, I. S., Cooper, G., Potter, B. V. L., Critchley, T., and Wonnacott, S. (1996). Nudicauline and elatine as potent norditerpenoid ligands at rat neuronal α-bungarotoxin binding sites: Importance of the 2-(methylsuccinimido)benzoyl moiety for neuronal nicotinic acetylcholine receptor binding. J. Med. Chem. 39:4860-4866.
117. Hayashi, E., Isogai, M., Kagawa, Y., Takayamagi, N., and Yamada, S. (1984). Neosurugatoxin, a specific antagonist of nicotinic acetylcholine receptors. J. Neurochem. 42:1491-1494.
118. Heidmann, T., Oswald, R. E., and Changeux, J.-P. (1983). Multiple sites of action for noncompetitive blockers on acetylcholine receptor rich membrane fragments from Torpedo marmorata. Biochemistry 22:3112-3127.
119. Hilmas, C., Pereira, E. F. R., Alkondon, M., Rassoulpour, A., Schwarcz, R., and Albuquerque, E. X. (2001). The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 21:7463-7473.
120. Hodgson, D. M., Maxwell, C. R., Wisedale, R., Matthews, I. R., Carpenter, K. J., Dickenson, A. H., and Wonnacott, S. (2001). 6-Substituted 2-azabicyclo[2.2.1]hept-5-enes by nitrogen-directed radical rearrangement: Synthesis of an epibatidine analogue with high binding affinity at the nicotinic acetylcholine receptor. J. Chem. Soc., Perkin Trans. 1 2001:3150-3158.
121. Holladay, M. W., Bai, H., Li, Y., Lin, N.-H., Daanen, J. F., Ryther, K. B., Wasicak, J. T., Kincaid, J. F., He, Y., Hettinger, A.-M., Huang, P., Anderson, D. J., Bannon, A. W., Buckley, M. J., Campbell, J. E., Donnelly-Roberts, D. L., Gunther, K. L., Kim, D. J. B., Kuntzweiler, T. A., Sullivan, J. P., Decker, M. W., and Arneric, S. P. (1998a). Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: Effect of pyridine and azetidine ring substitutions of nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Bioorg. Med. Chem. Lett. 8:2797-2802.
122. Holladay, M. W., Dart, M. J., and Lynch, J. K. (1997). Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J. Med. Chem. 40:4169-4194.
123. Holladay, M. W., Wasicak, J. T., Lin, N.-H., He, Y., Ryther, K. B., Bannon, A. W., Buckley, M. J., Kim, D. J. B., Decker, M. W., Anderson, D. J., Campbell, J. E., Kuntzweiler, T. A., Donnelly-Roberts, D. L., Piattoni-Kaplan, M., Briggs, C. A., Williams, M., and Arneric, S. P. (1998b). Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2- chloropyridine (ABT-594)., a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 41:407-412.
124. 3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. Mol. Pharmacol. 48:280-287.
125. Imming, P., Klaperski, P., Stubbs, M. T., Seitz, G., and Gündisch, D. (2001). Syntheses and evaluation of halogenated cystisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands. Eur. J. Med. Chem. 36:375-388.
126. Ing, H. R. (1931). Cytisine Part I. J. Chem. Soc. 2195-2203.
127. 3 nicotinic receptor. Eur. J. Med. Chem. 37:469-474.
128. Jacyno, J. M., Harwood, J. S., Lin, N. H., Cambell, J. E., Sullivan, J. P., and Holladay, M. W. (1996). Lycaconitine revisited: Partial synthesis and neuronal nicotinic acetylcholine receptor affinities. J. Nat. Prod. 59:707-709.
129. Jensen, A. A., Mikkelsen, I., Frølund, B., Bräuner-Osborne, H., Falch, E., and Krogsgaard-Larsen, P. (2003). Carbamoylcholine homologs: Novel and potent agonists at neuronal nicotinic acetylcholine receptors. Mol. Pharmacol. 64:865-875.
130. Jonnala, R. R., Graham, J. H. III, Terry, A. V., Jr., Beach, J. W., Young, J. A., and Buccafusco, J. J. (2003). Relative levels of cytoprotection produced by analogs of choline and the role of ay-nicotinic acetylcholine receptors. Synapse 47:262-269.
131. Kanne, D. B., and Abood, L. G. (1988). Synthesis and biological characterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicotinoids. J. Med. Chem. 31:506-509.
132. Karig, G., Large, J. M., Sharples, C. G., Sutherland, A., Gallagher, T.,
133. Kassiou, M., Bottlaender, M., Loc'h, C., Dolle, F., Musachio, J. L., Coulon, C., Ottaviani, M., Dannals, R. F., and Maziere, B. (2002). Pharmacological evaluation of a Br-76 analog of epibatidine: A potent ligand for studying brain nicotinic acetylcholine receptors. Synapse 45:95-104.
134. Kem, W. R., Mahnir, V. M., Papke, R. L., and Lingle, C. J. (1997). Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin- sensitive nicotinic receptors. J. Pharmacol. Exp. Ther. 283:979-992.
135. Kem, W. R. (1972). A study of the occurrence of anabaseine in Paranemertes and other nermertines. Toxicon 9:23-32.
136. Kim, K. D., Lerner-Marmaarosh, N., Saraswati, M., Kende, A. S., and Abood, L. G. (1994). 5-Isothiocyanonicotine: A high affinity irreversible ligand for brain nicotinic receptors. Biochem. Pharmacol. 47:1965-1967.
137. Kim, K. H., Lin, N.-H., and Anderson, D. J. (1996). Quantitative structure-activity relationships of nicotinic analogues as neuronal nicotinic acetylcholine receptor ligands. Bioorg. Med. Chem. 4:2211-2217.
138. King, H. (1946). Botanical origin of tube-curare. Nature 158:515-516.
139. 3H]phencyclidines to membrane preparation. Possible interaction with the cholinergic ionophore. FEBS Lett. 109:125-128.
140. Koren, A. O., Horti, A. G., Kimes, A., Scheffel, U., Ravert, H. T., London, E. D., and Dannals, R. F. (1997). Synthesis and Evaluation of benzo-Analogs of Epibatidine as Potential nAChR Ligands for PET Studies. XIIth International Symposium on Radiopharmaceutical Chemistry, Uppsala, Sweden, p. 518.
141. Kosuge, T., Tsuji, K., Hirai, K., Yamaquchi, O., Kamoto, T., and Iitake, (1981). Isolation and structure determination of a new marine toxin, neosurugatoxin, from the Japanese ivory shell, Babylonia Japonica. Tetrahedron Lett. 22:3417-3420.
142. 7 neuronal nicotinic acetylcholine receptor. Mol. Pharmacol. 53:283-294.
143. Krow, G. R., Cheung, O. H., Hu, Z., Huang, Q., Hutchinson, J., Liu, N., Nguyen, K. T., Ulrich, S., Yuan, J., Xiao, Y., Wypij, D. M., Zuo, F., and Carroll, P. J. (1999). Nitrogen bridge homoepibatidines. Syn-6-and syn-5(6-chloro-3-pyridyl)isoquinuclidines. Tetrahedron 55:7747-7756.
144. Krow, G. R., Yuan, J., Fang, Y., Meyer, M. D., Anderson, D. J., Campbell, J. E., and Carroll, P. J. (2000a). Synthesis of 3- and 5-endo-(6-chloro-3- pyridoxy)-methyl-2- azabicyclo[2.2.0]hexane and 3-endo-(6-chloro-3-pyridoxy)- methyl-2-azabicyclo[2.2.0]hex-5-ene. ABT-594 analogs. Tetrahedron 56:9227-9232.
145. Krow, G. R., Yuan, J., Huang, Q., Meyer, M. D., Anderson, D. J., Campbell, J. E., and Carroll, P. J. (2000b). Synthesis of 5- and 6-(6-chloro-3-pyridyl)-2-azabicyclo[2.2.0]hexanes. Epibatidine analogs. Tetrahedron 56:9233-9239.
146. Lands, A. M., and Archer, S. (1961). A study of the nicotinic action of 3-phenyltropane and related compounds. J. Med. Pharmacol. Chem. 2:449-460.
147. 2 neuronal nicotinic acetylcholine receptor. J. Med. Chem. 42:2227-2234.
148. Lee, M., Dukat, M., Liao, L., Flammia, D., Damaj, M. I., Martin, B., and Glennon, R. A. (2002). A comparison of the binding of three series of nicotinic ligands. Bioorg. Med. Chem. Lett. 12:1989-1992.
149. Lin, N.-H., Abreo, M. A., Gunn, D. E., Lebold, S. A., Lee, E. L., Wasicak, J. T., Hettinger, A.-M., Daanen, J. F., Garvey, D. S., Campbell, J. E., Sullivan, J. P., Williams, M., and Arneric, S. P. (1999). Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework. Bioorg. Med. Chem. Lett. 9:2747-2752.
150. Lin, N.-H., Carrera, G. M., Jr., and Anderson, D. J. (1994). Synthesis and evaluation of nicotine analogs as neuronal nicotinic acetylcholine receptor ligands. J. Med. Chem. 37:3542-3553.
151. Lin, N-H., Dong, L., Bunnelle, W. H., Anderson, D. J., and Meyer, M. D. (2002). Synthesis and biological evaluation of pyridine-modified analogues of 3-(2-aminoethoxy)pyridine as novel nicotinic receptor ligands. Bioorg. Med. Chem. Lett. 12:3321-3324.
152. Lin, N.-H., Gunn, D. E., Li, Y., He, Y., Bai, H., Ryther, K. B., Kuntzweiler, T., Donnelly-Roberts, D. L., Anderson, D. J., Campbell, J. E., Sullivan, J. P., Arneric, S. P., and Holladay, M. W. (1998). Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem. Lett. 8:249-254.
153. Lin, N.-H., Gunn, D. E., Ryther, K. B., Garvey, D. S., Donnelly-Roberts, D. L., Decker, M. W., Brioni, J. D., Buckley, M. J., Rodrigues, A. D., Marsh, K. G., Anderson, D. J., Buccafusco, J. J., Prendergast, M. A., Sullivan, J. P., Williams, M., Arneric, S. P., and Holladay, M. W. (1997). Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J. Med. Chem. 40:385-390.
154. Lin, N.-H., Li, Y., He, Y., Holladay, M. W., Kuntzweiler, T., Anderson, D. J., Campbell, J. E., and Arneric, S. P. (2001). Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543: A potent nicotinic receptor ligand. Bioorg. Med. Chem. Lett. 11:631-633.
155. 3H]nicotine to a single class of high affinity sites in rat brain. Mol. Pharmacol. 29:448-454.
156. Lloyd, G. K., and Williams, M. (2000). Neuronal nicotinic acetylcholine receptors as novel drug targets. J. Pharmacol. Exp. Ther. 292:461-467.
157. Luetje, C. W., Wada, K., Rogers, S., Abramson, S. N., Tsuji, K., Heinemann, S., and Patrick, J. (1990). Neurotoxins distinguish between different neuronal nicotinic acetylcholine receptor subunit compositions. J. Neurochem. 55:632-640.
158. Lukas, R. J. (1989). Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma. J. Pharmacol. Exp. Ther. 251:175-182.
159. Macallan, D. R. E., Lunt, G. G., Wonnacott, S., Swanson, K. L., Rapoport, H., and Albuquerque, E. X. (1988). Methyllycaconitine and (+)-anatoxin-a differentiate between nicotinic receptors in vertebrate and invertebrate nervous systems. FEBS Lett. 226:357-363.
160. 3 antagonist tropisetron (ICS 205-930). is a potent and selective alpha7 nicotinic receptor partial agonist. Biorg. Med. Chem. Lett. 11:319-321.
161. Maelicke, A., and Albuquerque, E. X. (2000). Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur. J. Pharmacol. 393:165-170.
162. Malpass, J. R., Hemmings, D. A., Wallis, A. L., Fletcher, S. R., and Patel, S. (2001). Synthesis and nicotinic acetylcholine binding properties of epibatidine homologues: Homoepibatidine and dihomoepibatidine. J. Chem. Soc., Perkin Trans. 1 2001:1044-1050.
163. 4-dimethylpiperazinium iodide (DMPP) with central nicotinic action. Bioorg. Med. Chem. 7:457-465.
164. 2 subunit. J. Pharmacol. Exp. Ther. 289:1090-1103.
165. 2 null mutant mice. J. Neurochem. 81:1102-1115.
166. Matsubayashi, H., II, Alkondon, M., Pereira, E. F. R., Swanson, K. L., and Albuquerque, E. X. (1998). Strychnine: A potent competitive antagonist of α-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 284:904-913.
167. McIntosh, J. M., Santos, A. D., and Olivera, B. M. (1999). Conus peptides targeted to specific nicotinic acetylreceptor subtypes. Annu. Rev. Biochem. 68:59-88.
168. Meyer, M. D., Decker, M. W., Rueter, L. E., Anderson, D. J., Dart, M. J., Kim, K. H., Sullivan, J. P., and Williams, M. (2000). The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain. Eur. J. Pharmacol. 393:171-177.
169. Meyer, E. M., deFiebre, C. M., Hunter, B. E., Simpkins, C. E., Franworth, N., and deFiebre, F. E. C. (1994). Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behavior. Drug Dev. Res. 31:127-134.
170. 3H] tetracaine, a nondesensitizing noncompetitive antagonist. Mol. Pharmacol. 56:290-299.
171. Moltzen, E. K., and Bjornholm, B. (1995). Medicinal chemistry of muscarinic agonists: Developments since 1990. Drugs Future 20:37-54.
172. 7 nicotinic acetylcholine receptor. J. Med. Chem. 43:4045-4050.
173. Nielsen, S. F., Nielsen, E. Ø., Olsen, G. M., Liljefors, T., and Peters, D. (2000). Novel potent ligands for the central nicotinic acetylcholine receptor: Synthesis, receptor binding, and 3D-QSAR analysis. J. Med. Chem. 43:2217-2226.
174. Olesen, P. B., Swedberg, M. D. B., and Rimvall, K. (1998). 3-(5-Alkylamino-4-isoxazolyl)-1,2,5,6-tetrahydropyridines: A novel class of central nicotinic receptor ligands. Bioorg. Med. Chem. 6:1623-1629.
175. Olivo, H. F., Colby, D. A., and Hemenway, M. S. (1999). Syntheses of new open-ring and homo-epibatidine analogues from tropinone. J. Org. Chem. 64:4966-4968.
176. Olesen, P. H., Tønder, J. E., Hansen, J. B., Hansen, H. C., and Rimvall, K. (2000). Bioisosteric replacement strategy for the synthesis of 1-azacyclic compounds with high affinity for the central nicotinic cholinergic receptors. Bioorg. Med. Chem. 8:1443-1450.
177. 3H]Cytisine binding to nicotinic cholinergic receptors in brain. Mol. Pharmacol. 39:9-12.
178. Papke, R. L., Bencherif, M., and Lippiello, P. (1996). An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype. Neurosci. Lett. 213:201-204.
179. Papke, R. L., and Porter-Papke, J. W. (2002). Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis. Br. J. Pharmacol. 137:49-61.
180. Papke, R. L., Porter-Papke, J. K., and Rose, G. M. (2004). Activity of α7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes. Bioorg. Med. Chem. Lett. 14:1849-1853.
181. Papke, R. L., and Thinschmidt, J. S. (1998). The correction of alpha 7 nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes. Neurosci. Lett. 256:163-166.
182. Pedersen, S. E. (1995). Site-selective photoaffinity labeling of the Torpedo californica nicotinic acetylcholine receptor by azide derivatives of ethidium bromide. Mol. Pharmacol. 47:1-9.
183. 2-receptors. J. Med. Chem. 41:2047-2055.
184. 2 subtype of neuronal nicotinic acetylcholine receptor stably expressed in fibroblasts cells. J. Pharmacol. Exp. Ther. 270:768-778.
185. Rádl, S., Hezký, P., Hafner, W., Budinský, M., and Hejnová, L. (2000). Synthesis and binding studies of some epibatidine analogues. Bioorg. Med. Chem. Lett. 10:55-58.
186. Romanelli, M. N., and Gualtieri, F. (2003). Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. Med. Res. Rev. 23:393-426.
187. 4-phenylpiperazinium iodide (DMPP). J. Med. Chem. 44:3946-3955.
188. Sacaan, A. I., Reid, R. T., Santori, E. M., Adams, P., Correa, L. D., Mahaffy, L. S., Bleicher, L., Cosford, N. D. P., Stauderman, K. A., McDonald, I. A., Rao, T. S., and Lloyd, G. K. (1997). Pharmacological characterization of SIB-1765F: A novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280:373-383.
189. Saji, H., Watanabe, A., Magata, Y., Ohmomo, Y., Kiyono, Y., Yamada, Y., Iida, Y., Yonekura, Y., Konishi, J., and Yokoyama, A. (1997). Synthesis and characterization of radioiodinated (S)-5-iodonicotine: A new ligand for potential imaging of brain nicotinic cholinergic receptors by single photon emission computed tomography. Chem. Pharmacol. Bull. 45:284-290.
190. 3H] metabolites in rat striatum by nicotinic drugs. Brain Res. 242:99-106.
191. Saraswati, M., Lerner-Marmarosh, N., Wang, D. X., Shen, S.-S., Sharma, V., and Abood, L. G. (1994). Structure-activity studies of N,N-dialkyl and cycloalkyl carbamate esters of dimethylethanolamine and choline with nicotinic and muscarinic receptors. Drug Dev. Res. 31:142-146.
192. Schmidt, J. D. (2000). Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem. 7:749-800.
193. Schrattenholz, A., Pereira, E. F. R., Roth, U., Weber, K.-H., Albuquerque, E. X., and Maelicke, A. (1996). Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 49:1-6.
194. Seerden, J.-P. G., Tulp, M. Th. M., Scheeren, H. W., and Kruse, C. G. (1998). Synthesis and structure-activity data of some new epibatidine analogues. Bioorg. Med. Chem. 6:2103-2110.
195. Sharples, C. G. V., Karig, G., Simpson, G. L., Spencer, J. A., Wright, E., Millar, N. S., Wonnacott, S., and Gallagher, T. (2002). Synthesis and pharmacological characterization of novel analogues of the nicotinic acetylcholine receptor agonist (±)-UB-165. J. Med. Chem. 45:3235-3245.
196. Shaw, K.-P., Aracava, Y., Akaike, A., Daly, J. W., Rickett, D. L., and Albuquerque, E. X. (1985). The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol. 28:527-538.
197. Sihver, W., Nordberg, A., Långström, B., Mukhin, A. G., Koren, A. O., Kimes, A. S., and London, E. D. (2000). Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav. Brain. Res. 113:143-157.
198. Simsek, R., Chang-Fong, J., Lee, M., Dukat, M., Damaj, M. I., Martin, B. R., and Glennon, R. A. (2003). Quaternary ammonium 3-(aminoethoxy)pyridines as antinociceptive agents. Bioorg. Med. Chem. Lett. 13:2917-2920.
199. Singh, S., Avor, K. S., Pouw, B., Seale, T. W., and Basmadjian, G. P. (1999). Design and synthesis of isooxazole containing bioisosteres of epibatidine as potent nicotinic acetylcholine receptor agonists. Chem. Pharmacol. Bull. 47:1501-1505.
200. Slater, Y. E., Houlihan, L. M., Maskell, P. D., Exley, R., Bermúdez, I., Lukas, R. J., Valdivia, A. C., and Cassels, B. K. (2003). Halogenated cystisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 44:503-515.
201. Small, G., Erkinjuntti, T., Kurz, A., Lilienfeld, S. (2003). Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. CNS Drugs 17:905-914.
202. Smith, B. P., Tyler, M. J., Kaneko, T., Garraffo, H. M., Spande, T. F., and Daly, J. W. (2002). Evidence for biosynthesis of pseudophrynamine alkaloids by an Australian myobatrachid frog (Pseudophryne) and sequestration of dietary pumiliotoxins. J. Nat. Prod. 65:439-447.
203. Souccar, C., Varanda, W. A., Aronstam, R. S., Daly, J. W., and Albuquerque, E. X. (1984a). Interactions of gephyrotoxin with the acetylcholine receptor-ionic channel complex. II. Enhancement of desensitization. Mol. Pharmacol. 25:395-400.
204. Souccar, C., Varanda, W. A., Daly, J. W., and Albuquerque, E. X. (1984b). Interactions of gephyrotoxin with the acetylcholine receptor-ionic channel complex. I. Blockade of the ionic channel. Mol. Pharmacol. 25:384-394.
205. Spande, T. F., Garraffo, H. M., Edwards, M. W., Yeh, H. J. C., Pannell, L., and Daly, J. W. (1992). Epibatidine: A novel (chloropyridyl) azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J. Am. Chem. Soc. 114:3475-3478.
206. Spang, J. E., Bertrand, S., Westera, G., Patt, J. T., Schubiger, P. A., and Bertrand, D. (2000). Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors. Chem. Biol. 7:545-555.
207. Spivak, C. E., Gund, T. M., Liang, R. F., and Waters, J. A. (1986). Structural and electronic requirements for potent agonists at a nicotinic receptor. Eur. J. Pharmacol. 120:127-131.
208. Spivak, C. E., Maleque, M. A., Oliveira, A. C., Masukawa, L. M., Tokuyama, T., Daly, J. W., and Albuquerque, E. X. (1982). Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes. Mol. Pharmacol. 21:351-361.
209. Spivak, C. E., Waters, J., Witkop, B., and Albuquerque, E. X. (1983). Potencies and channel properties induced by semirigid agonists at frog nicotinic acetylcholine receptors. Mol. Pharmacol. 23:337-343.
210. 4 stably expressed in HEK793 cells. J. Pharmacol. Exp. Ther. 284:777-789.
211. Storch, A., Schrattenholz, A., Cooper, J. C., Abdel Ghani, E. M., Gutbrod, O., Weber, K.-H., Reinhardt, S., Lobron, C., Hermsen, B., Soskic, V., Pereira, E. F. R., Albuquerque, E. X., Methfessel, C., and Maelicke, A. (1995). Physostigmine, galanthamine and codeine act as noncompetitive nicotinic agonists on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 290:207-219.
212. Sutherland, A., Gallagher, T., Sharples, C. G., and Wonnacott, S. (2003). Synthesis of two fluoro analogues of the nicotinic acetylcholine receptor agonist UB-165. J. Org. Chem. 68:2475-2478.
213. Swanson, K. L., Allen, C. N., Aronstam, R. S., Rapoport, H., and Albuquerque, E. X. (1986). Molecular mechanisms of the potent and stereospecific nicotinic receptor agonist (+)-anatoxin-a. Mol. Pharmacol. 29:250-257.
214. Tabachnick, I. I. A., Roth, F. E., Mershon, J., Rubin, A. A., Eckhardt, E. T., and Govier, W. M. (1958). Enzymic and pharmacologic comparison of imidazoleacetylcholine with two related choline esters, murexine and dihydromurexine. J. Pharmacol. Exp. Ther. 123:98-103.
215. 2 nicotinic acetylcholine receptors: Structure-activity relationships and molecular modelling. Curr. Med. Chem. 8:651-674.
216. Tønder, J. E., Hansen, J. B., Begtrup, M., Pettersson, I., Rimvall, K., Christensen, B., Ehrbar, U., and Olesen, P. H. (1999). Improving the nicotinic pharmacophore with a series of (isoxazole)methylene-1-azacyclic compounds: Synthesis, structure-activity relationship, and molecular modeling. J. Med. Chem. 42:4970-4980.
217. Toma, L., Quadrelli, P., Bunnelle, W. H., Anderson, D. J., Meyer, M. D., Cignarella, G., Gelain, A., and Barlocco, D. (2002). 6-Chloropyridazin-3-yl derivatives active as nicotinic agents: Synthesis, binding, and modeling studies. J. Med. Chem. 45:4011-4017.
218. Tsuda, Y., and Sano, T. (1996). Erythrina and related alkaloids. In Cordell, G. A. (ed.), The Alkaloids, Vol. 48, Academic Press, New York. pp. 249-337.
219. Ullrich, T., Krich, S., Binder, D., Mereiter, K., Anderson, D. J., Meyer, M. D., and Pyerin, M. (2002). Conformationally constrained nicotines: Polycyclic, bridged, and spiro-annulated analogues as novel ligands for the nicotinic acetylcholine receptor. J. Med. Chem. 45:4047-4054.
220. Vernier, J.-M., El-Abdellaoui, H., Holsenback, H., Cosford, N. D. P., Bleicher, L., Barker, G., Bontempi, B., Chavez-Noriega, L., Menzaghi, F., Rao, T. S., Reid, R., Sacaan, A. I., Suto, C., Washburn, M., Lloyd, G. K., and McDonald, I. A. (1999). 4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]-phenol hydrochloride (SIB-1553 A): A novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors. J. Med. Chem. 42:1684-1686.
221. 3H]nicotine binding and psychotropic potency. Drug Dev. Res. 45:10-16.
222. Wang, F., Gerzanich, V., Wells, G. B., Anand, R., Peng, X., Keyser, K., and Lindstrom, J. (1996). Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2, and β4 subunits. J. Biol. Chem. 271:17656-17665.
223. Wang, G. K., Molinaro, S., and Schmidt, J. (1978). Ligand responses of α-bungarotoxin binding sites from skeletal muscle and optic lobe of the chick. J. Biol. Chem. 253:8507-8512.
224. Ward, J. M., Cockcroft, V. B., Lunt, G. G., Smillie, F. S., and Wonnacott, S. (1990). Methyllycaconitine: A selective probe for neuronal α-bungarotoxin binding sites. FEBS Lett. 270:45-48.
225. Ward, J. S., Merritt, L., Bymaster, F. P., and Calligaro, D. O. (1994). Isoarecolones and arecolones: Selective central nicotinic agonists that cross the blood brain barrier. Bioorg. Med. Chem. Lett. 4:573-578.
226. Warnick, J. E., Jessup, P. J., Overman, L. E., Eldefrawi, M. E., Nimit, Y., Daly, J. W., and Albuquerque, E. X. (1982). Pumiliotoxin-C and synthetic analogues: A new class of nicotinic antagonists. Mol. Pharmacol. 22:565-573.
227. Waters, J. A., Spivak, C. E., Hermsmeier, M., Yadav, J. S., Liang, R. F., and Gund, T. M. (1988). Synthesis. pharmacology and molecular modeling studies of semirigid, nicotinic agonists. J. Med. Chem. 31:545-554.
228. Wei, Z. L., Petukhov, P. A., Xiao, Y., Tückmantel, W., George, C., Kellar, K. J., and Kozikowski, A. P. (2003a). Synthesis, nicotinic acetylcholine receptor binding affinities, and molecular modeling of constrained epibatidine analogues. J. Med. Chem. 46:921-924.
229. Wei, Z.-L., Xiao, Y., George, C., Kellar, K. J., and Kozikowski, A. P. (2003b). Functionalization of the alicyclic skeleton of epibatidine: Synthesis and nicotinic acetylcholine receptor binding affinities of epibatidine analogues. Org. Biomol. Chem. 1:3878-3881.
230. Wheeler, J. W., Olubajo, O., Storm, C. B., and Duffield, R. M. (1981). Anabaseine: Venom alkaloid of Aphaenogaster ants. Science 211:1051-1052.
231. 7 neuronal nicotinic receptors. J. Pharmacol. Exp. Ther. 304:400-410.
232. Wonnacott, S., Jackman, S., Swanson, K. L., Rapoport, H., and Albuquerque, E. X. (1991). Nicotinic pharmacology of anatoxin analogs. II. Side chain structure-activity relationships at neuronal nicotinic ligand binding sites. J. Pharmacol. Exp. Ther. 259:387-391.
233. Wonnacott, S., Swanson, K. L., Albuquerque, E. X., Huby, N. J. S., Thompson, P., and Gallagher, T. (1992). Homoanatoxin: A potent analogue of anatoxin-a. Biochem. Pharmacol. 43:419-423.
234. Wright, E., Gallagher, T., Sharples, C. G. V., and Wonnacott, S. (1997). Synthesis of UB-165: A novel nicotinic ligand and anatoxin-a/epibatidine hybrid. Bioorg. Med. Chem. Lett. 7:2867-2870.
235. Xu, R., Bai, D., Chu, G., Tao, J., and Zhu, X. (1996). Synthesis and analgesic activity of epibatidine analogues. Bioorg. Med. Chem. Lett. 6:279-282.
236. Xu, R., Dwoskin, L. P., Grinevich, V. P., Deaciuc, G., and Crooks, P. A. (2001). Neuronal nicotinic acetylcholine receptor binding affinities of boron-containing nicotine analogues. Bioorg. Med. Chem. Lett. 11:1245-1248.
237. Xu, R., Dwoskin, P., Grinevich, V., Sumithran, S. P., and Crooks, P. A. (2002). Synthesis and evaluation of conformationally restricted pyridine n-alkylated nicotine analogs as nicotinic acetylcholine receptor antagonists. Drug Dev. Res. 55:173-186.
238. Zhang, C., Gyermek, L., and Trudell, M. L. (1997). Synthesis of optically pure epibatidine analogs: (1R,2R,5S)-2β-(2-chloro-5-pyridinyl)-8- azabicyclo[3.2.1]octane and (1R,2S,5S)-2α-(2-chloro-5-pyridinyl)-8- azabicyclo[3.2.1]octane from (-)-cocaine. Tetrahedron Lett. 38:5619-5622.
239. 7 nicotinic acetylcholine receptors. Bioorg. Med. Chem. Lett. 13:525-527.
240. Zhang, X., Gong, Z.-H., Fasth, K. J., Långström, B., and Nordberg, A. (1998). Interaction of the nicotinic agonist (R, S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidine (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. Neurochem. Int. 32:435-441.